News | January 10, 2024
Tata 1mg and Vitonnix UK get into an exclusive partnership in India
Launch innovative vitamin sublingual sprays
Launch innovative vitamin sublingual sprays
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The company received gross proceeds of approximately US$1.7 million and net proceeds,
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Subscribe To Our Newsletter & Stay Updated
